|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
If you have a question about this talk, please contact Janet Gibson.
Political extremism appears to be all around us. Populists, xenophobes and, some might argue, fascists seem to be on the rise. Many trace the current challenge to liberal representative democracy to the legacy of the post-2008 financial crisis and economic scarcity, recycling earlier interpretations of the rise of historic fascism. But what is really driving support for political extremism in the West today? What do we really know about those who vote for these parties, including their backgrounds and concerns? This lecture will examine the drivers of support for contemporary forms of political radicalism and extremism, from the election of Donald Trump to the vote for Brexit in the United Kingdom and to forthcoming elections in France, the Netherlands and Germany.
Matthew J. Goodwin is Professor of Politics at Rutherford College, University of Kent, and Senior Visiting Fellow at Chatham House. His books include Revolt on the Right: Explaining Public Support for the Radical Right in Britain (published by Routledge) and a forthcoming study of the Brexit vote with Cambridge University Press. He shares much of his research and thoughts on Twitter (@GoodwinMJ) and his website matthewjgoodwin.org
This talk is part of the Darwin College Lecture Series series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
Other listsBabbage Seminar Series Centre for Family Research Seminar Series Statistical Laboratory info aggregator
Other talksCCHG series: Political Geology Workshop Mechanisms of Apathy in Health and Parkinson’s Disease The distribution of oxygen in the Earth’s mantle The gifts of Athena revisited: protectionism, regulation and the British Industrial Revolution, 1700–1800 Change and necessity: forest resilience and conservation for the 21st century Validation & testing of novel therapeutic targets to treat osteosarcoma